Roche’s Glofitamab, a CD20xCD3 bispecific mab, shows durable responses in R/R DLBCL in a pivotal phase II trial. Can Epcoritamab beat the CR rate of 39%? For More Information- https://www.delveinsight.com/asco-conference/article/roche-glofitamab?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage

1. Roche’s Glofitamab August 12, 2022
P a g e 1 | 3
Roche’s Glofitamab, a CD20xCD3 bispecific mab, shows
durable responses in R/R DLBCL in a pivotal phase II trial.
Can Epcoritamab beat the CR rate of 39%?
Roche’s Glofitamab: ASCO 2022
Roche revealed the impressive findings from the Phase II expansion study of Glofitamab in
the patients with R/R DLBCL (Abstract # 7500)
Glofitamab is an investigational CD20xCD3 T-cell engaging bispecific antibody designed to
target CD20 on the surface of B-cells and CD3 on the surface of T-cells. Moreover,
glofitamab is a part of Roche's larger bispecific antibody development program, which
could lead to a new immunotherapy-based treatment for a variety of blood malignancies.
According to the results presented at the ASCO 2022 conference, as of 14 March 2022, a
total of 155 patients were evaluable, with a median follow-up of 12.6 months. The
elicited complete response (CR) was 39.4%, followed by an overall response rate
(ORR) of 51.6%. Moreover, these data were more impressive since 34% of patients were
after receiving CAR-T therapy, and the CR rate in these patients was 35%.
Most importantly, the impact of the CR rate sets the bar for other rival competitors
like AbbVie, Genmab, etc. As per the independent review committee, the median duration
of response (DoR) in the trial was 10.6 months, and the median progression-free survival
(PFS) was 12.6 months.
In addition to that, the median OS (Overall Survival) was 11.5 months. In terms of safety,
glofitamab was well tolerated with low-grade CRS (Cytokine release syndrome).
KOL insights

2. Roche’s Glofitamab August 12, 2022
P a g e 2 | 3
“These glofitamab data suggest that patients may be able to achieve durable responses
with a set course of treatment that they don’t have to take continuously until disease
progression.” –Expert Opinion.
“I’m encouraged by these data as they signify new hope for these patients who otherwise
have limited effective treatment options and have faced disappointment from their
disease not responding to multiple prior rounds of treatments”–Expert Opinion.
Conclusion
The recent data on glofitamab brings it one step closer to the goal of finding solutions for
people with heavily pretreated diffuse large B-cell lymphoma, which often relapses and
becomes more aggressive. Moreover, the potential of glofitamab as a new fixed-duration,
readily available treatment could be instrumental to improving outcomes for people with
this difficult-to-treat cancer who otherwise have limited options.
The consistent CR rate was achieved early and durable after the fixed treatment duration.
Based on these findings, the Phase II expansion study data have been submitted for
approval to the European Medicines Agency (EMA), and submissions to additional health
authorities worldwide, including the US FDA, are also planned this year.
Additionally, glofitamab could be an effective companion to Roche’s CD79b-directed
ADC Polivy (Polatuzumab Vedotin), which was approved in the EU earlier this week for
previously untreated DLBCL.
Companies- AbbVie, Roche (Genentech), Bristol Myers Squibb, Regeneron
Pharmaceuticals, Amgen, Incyte Corporation, Merck Sharp & Dohme LLC, Sanofi, IGM
Biosciences, Gilead Sciences, Allogene Therapeutics, Sorrento Therapeutics, Novartis,
MorphoSys, Kite Therapeutics, Beigene, Seagen, Curocell, TG Therapeutics, and others.
Latest Pharmaceuticals Research Reports 2022 by DelveInsight
 Medical Marijuana Market
 NPC Market
 Tourette Syndrome Market
 Oncolytic Virus Cancer Therapy Pipeline
 Myeloproliferative Neoplasms Market
 Shigellosis Market
 CAR-T Pipeline
 Urology Ultrasounds Devices Market
 Myopia Treatment Devices Market

3. Roche’s Glofitamab August 12, 2022
P a g e 3 | 3
 Alkaptonuria Market
 Atopic Dermatitis AD Market
 Axillary Hyperhidrosis Market
 Fabry Disease Market
 Rubella Market
 Post-Transplant Lymphoproliferative Disorder Market
 Coccidioidomycosis Market
 Focal Segmental Glomerulosclerosis Market
 Pigment Epithelial Detachment Market
 Farber’s Disease Market
 Advanced Liver Cancer Market
 Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome Market
 Opioid-related Disorders Market
 Myopia Progression Market Share
 Chronic Venous Ulceration Market
 Ptosis Market
 Human Papillomavirus-positive Oropharyngeal Cancer Market
 Trauma Fixation Devices Market
 Eosinophilic Disorder Market
 Epidemic Parotitis Market
 Cystinuria Market
 Familial Lipoprotein Lipase Deficiency Market